Common Contracts
4 similar Right of First Refusal and Co-Sale Agreement contracts by PureTech Health PLC, Kiromic Biopharma, Inc.
AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENTRight of First Refusal and Co-Sale Agreement • October 27th, 2020 • PureTech Health PLC • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (this “Agreement”), is made as of the 30th day of June, 2020 by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), the Investors (as defined below) listed on Schedule A and the Key Holders (as defined below) listed on Schedule B.
RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENTRight of First Refusal and Co-Sale Agreement • October 27th, 2020 • PureTech Health PLC • Pharmaceutical preparations • Delaware
THIS RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (this “Agreement”), is made as of the 18th day of December, 2017 by and among Entrega, Inc., a Delaware corporation (the “Company”), the Investors listed on Schedule A and the Key Holders listed on Schedule B.
FOLLICA, INCORPORATED FIFTH AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO- SALE AGREEMENT Dated as of July 19, 2019Right of First Refusal and Co-Sale Agreement • October 27th, 2020 • PureTech Health PLC • Pharmaceutical preparations • Delaware
This FIFTH AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (the “Agreement”) is made as of the 19th day of July, 2019 by and among Follica, Incorporated, a Delaware corporation (the “Company”), the Investors listed on Schedule A and the Key Holders listed on Schedule B. All capitalized terms used but not defined herein shall have the meanings set forth in the Note Conversion Agreement (as defined below).
EXHIBIT E FORM OF RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENTRight of First Refusal and Co-Sale Agreement • April 8th, 2020 • Kiromic Biopharma, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (this “Agreement”), is made as of the 7th day of September, 2019 by and among Kiromic, Inc., a Delaware corporation (the “Company”), the Investors (as defined below) listed on Schedule A and the Key Holders (as defined below) listed on Schedule B.
